1. Scrip
  2. >>Business

Novartis Sees Pliant’s NASH Program Offering Pathway To Treating Sickest Patients

 
• By Joseph Haas

Swiss pharma thinks targeted integrin inhibition could be part of the approach to treating cirrhotic NASH patients, those most at risk of needing a liver transplant.

Novartis_Building
Novartis' partnership with Pliant is aimed at treating the sickest NASH patients

Novartis AG has been active in non-alcoholic steatohepatitis (NASH) development and deal-making in recent years, but its $80m upfront commitment to Pliant Therapeutics for a preclinical alpha V beta 1 integrin inhibitor still caught attention last October. In an interview, executives from both companies explained that PLN-1474 and potential follow-on integrin inhibitors may help Novartis develop a therapy for the sickest NASH patients, those with cirrhosis.

Then-privately held Pliant had multiple suitors for its preclinical integrin inhibitor program after presenting data showing antifibrotic properties for its molecules from testing in liver samples of late-stage NASH patients,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Deal Watch: QurAlis Targets Fragile-X Syndrome In Deals With Quiver, UMass

 
• By Joseph Haas

Plus the end of Sanofi’s six-target alliance with IGM, OmniAb’s deals with Veraxa and Angelini, alliances involving Skye/Arecor, Genprex/UTHealth Houston and more.

GSK’s Nucala Set For Dupixent Face-Off After FDA COPD Nod

 
• By Kevin Grogan

The UK major's asthma drug gets a key expanded approval.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.

More from Business